Literature DB >> 12152961

Acute management of atrial fibrillation: Part II. Prevention of thromboembolic complications.

Dana E King1, Lori M Dickerson, Jonathan L Sack.   

Abstract

Family physicians should be familiar with the acute management of atrial fibrillation and the initiation of chronic therapy for this common arrhythmia. Initial management should include hemodynamic stabilization, rate control, restoration of sinus rhythm, and initiation of antithrombotic therapy. Part II of this two-part article focuses on the prevention of thromboembolic complications using anticoagulation. Heparin is routinely administered before medical or electrical cardioversion. Warfarin is used in patients with persistent atrial fibrillation who are at higher risk for thromboembolic complications because of advanced age, history of coronary artery disease or stroke, or presence of left-sided heart failure. Aspirin is preferred in patients at low risk for thromboembolic complications and patients with a high risk for falls, a history of noncompliance, active bleeding, or poorly controlled hypertension. The recommendations provided in this article are consistent with guidelines published by the American Heart Association and the Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152961

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

1.  Atrial Fibrillation: a Patient's Guide to Understanding Drug Therapy.

Authors:  Ragini S Bhakta
Journal:  J Atr Fibrillation       Date:  2008-12-01

Review 2.  Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options.

Authors:  Sérgio Barra; Simon Fynn
Journal:  J Saudi Heart Assoc       Date:  2014-09-03

3.  Atrial fibrillation anticoagulation care in a large urban family medicine practice.

Authors:  Alissia Valentinis; Noah Ivers; Sacha Bhatia; Nazanin Meshkat; Kori Leblanc; Andrew Ha; Dante Morra
Journal:  Can Fam Physician       Date:  2014-03       Impact factor: 3.275

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.